Brief: Rallybio Announces In-Licensing Of Potential First-In-Class Preclinical Antibody Candidate From Sanofi

Rallybio

10/05/2022 12:37

May 10 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO ANNOUNCES IN-LICENSING OF POTENTIAL
FIRST-IN-CLASS
PRECLINICAL ANTIBODY CANDIDATE FROM SANOFI
    * RALLYBIO CORP - UNDER TERMS OF LICENSE AGREEMENT, CO WILL
MAKE
AN UPFRONT CASH PAYMENT OF $3 MILLION TO SANOFI
    * RALLYBIO - UNDER LICENSE AGREEMENT, CO WILL PAY
DEVELOPMENT &
COMMERCIAL MILESTONES, & MID TO HIGH SINGLE DIGIT ROYALTIES ON
NET SALES TO SANOFI

Source text for Eikon:  ID:nBw6DbNp6a 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))